Chronic Lymphocytic Leukemia — FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Citation(s)
A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination With Rituximab or Obinutuzumab in Subjects With Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia